文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

胃肠道肿瘤脑转移患者立体定向放射外科治疗结果:802例患者回顾性队列研究及胃肠道分级预后评估系统效度检验

Stereotactic Radiosurgery Results for Patients With Brain Metastases From Gastrointestinal Cancer: A Retrospective Cohort Study of 802 Patients With GI-GPA Validity Test.
PubMed 文献 · Adv Radiat Oncol · 2021-05-18

这项回顾性队列研究纳入1998至2018年接受伽玛刀立体定向放射外科治疗的802例胃肠道肿瘤脑转移患者,评估治疗后生存及胃肠道分级预后评估系统与改良递归 partitioning 分析系统的适用性。结果显示胃肠道分级预后评估系统各亚组中位生存期差异有统计学意义,但1.5至2.0与2.5至3.0亚组间无显著差异;改良递归 partitioning 分析系统各亚组曲线无重叠。作者认为胃肠道分级预后评估系统具有实用性,胃肠道分级预后评估1.5至2.0或以上、或改良递归 partitioning 分析2b或以上的患者可考虑单独立体定向放射外科治疗。

要点

  • 802例胃肠道肿瘤脑转移患者接受伽玛刀立体定向放射外科治疗后中位生存期为5.7个月。
  • 胃肠道分级预后评估系统4个亚组中位生存期分别为3.5、6.1、7.7、11.0个月,分层P<.0001。
  • 胃肠道分级预后评估1.5至2.0与2.5至3.0亚组间中位生存期无显著差异(P=.073)。

核心结论

  • 本研究明确展示了胃肠道分级预后评估系统的实用性。
  • 作者认为胃肠道分级预后评估1.5至2.0或以上、或改良递归 partitioning 分析2b或以上的患者是单独立体定向放射外科治疗的有利候选者。

研究设计与样本

  • 本研究为经机构审查委员会批准的回顾性队列研究,基于2个数据库纳入802例胃肠道肿瘤患者。
  • 患者于1998至2018年期间由2名经验丰富的神经外科医生行伽玛刀立体定向放射外科治疗。
  • 采用Kaplan-Meier法确定立体定向放射外科治疗后生存时间,采用竞争风险分析估计次要终点的累积发生率。

主要发现

  • 立体定向放射外科治疗后中位生存期为5.7个月。
  • 胃肠道分级预后评估系统0至1.0、1.5至2.0、2.5至3.0、3.5至4.0亚组的中位生存期分别为3.5、6.1、7.7、11.0个月(分层P<.0001)。
  • 胃肠道分级预后评估1.5至2.0与2.5至3.0亚组间中位生存期无显著差异(P=.073)。
  • 改良递归 partitioning 分析系统3个亚组对应的3条曲线无重叠,1+2a与2b亚组间(P<.0001)及2b与2c+3亚组间(P<.0001)中位生存期差异有统计学意义。
  • 多因素分析显示较好的卡氏功能状态评分、单发肿瘤、原发肿瘤控制良好及无脑外转移是生存期较长的显著预测因素。

临床怎么用

  • 作者认为胃肠道分级预后评估1.5至2.0或以上、或改良递归 partitioning 分析2b或以上的患者是单独立体定向放射外科治疗的有利候选者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of stereotactic radiosurgery (SRS) alone for patients with gastrointestinal (GI) cancer has yet to be established based on a large patient series. We analyzed post-SRS treatment results and reappraised whether either the GI graded prognostic assessment (GPA) system or modified-recursive partitioning assessment (M-RPA) system was applicable to our 802 SRS-treated patients with GI cancer with brain metastases. METHODS AND MATERIALS: This was an institutional review board approved retrospective cohort study 2 database comprising 802 patients with GI cancer treated with gamma-knife SRS by 2 experienced neurosurgeons during the 1998 to 2018 period. The Kaplan-Meier method was applied to determine post-SRS survival times, and competing risk analyses were used to estimate cumulative incidences of the secondary endpoints. RESULTS: The median survival time (MST; months) after SRS was 5.7. With the GI GPA system, MSTs were 3.5/6.1/7.7/11.0 in the 4 subgroups, that is, 0 to 1.0/1.5 to 2.0/2.5 to 3.0/3.5 to 4.0, respectively (stratified P < .0001). However, there was no significant MST difference between 2 of the subgroups, GI-GPA 1.5 to 2.0 and 2.5 to 3.0 (P = .073). In contrast, using the M-RPA system, 3 plot lines corresponding to the 3 subgroups showed no overlap and the MST differences between the subgroups with M-RPA were 1 + 2a versus 2b (P < .0001) and 2b versus 2c + 3 (P < .0001). Better Karnofsky performance status score, solitary tumor, well-controlled primary cancer, and the absence of extracerebral metastases were shown by multivariable analysis to be significant predictors of longer survival. The crude and cumulative incidences of neurologic death, neurologic deterioration, local recurrence, salvage whole brain radiation therapy, and SRS-related complications did not differ significantly between the 2 patient groups, with upper and lower GI cancers. CONCLUSIONS: This study clearly demonstrated the usefulness of the GI GPA. Patients with GI GPA 1.5 to 2.0 or better or M-RPA 2b or better are considered to be favorable candidates for treatment with SRS alone.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yamamoto M, Serizawa T, Sato Y, et al. Stereotactic Radiosurgery Results for Patients With Brain Metastases From Gastrointestinal Cancer: A Retrospective Cohort Study of 802 Patients With GI-GPA Validity Test. Adv Radiat Oncol. 2021. PMID: 34934852. doi:10.1016/j.adro.2021.100721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。